{"id":21,"date":"2023-10-11T09:11:45","date_gmt":"2023-10-11T08:11:45","guid":{"rendered":"https:\/\/www.shs-capital.eu\/?page_id=21"},"modified":"2025-08-29T10:46:04","modified_gmt":"2025-08-29T09:46:04","slug":"investors","status":"publish","type":"page","link":"https:\/\/www.shs-capital.eu\/investors\/","title":{"rendered":"Our Investors"},"content":{"rendered":"\n\n \n
\n
<\/div>\n \"\"\n \n

Trusted By Investors for more than 30 years<\/h1>\n
\n Get in Touch<\/a>\n More about Investment Strategy<\/a>\n <\/div> <\/div>\n <\/section>\n \n\n\n
Home<\/span><\/a><\/span><\/section>\n\n\n

Investing
With SHS<\/h2>\n\n\n\n

We are the leading German healthcare-only specialized Private Equity Fund.<\/p>\n\n\n\n

\"\"<\/figure>
\n

Limited Partners can participate in a portfolio of high-growing companies in the healthcare and life science industry.<\/p>\n\n\n\n

Since over 30 years, investors can rely on our stable, local investment team with aggregated 100 years of experience in the private equity industry.<\/p>\n\n\n\n

From a pool of more than 1000 opportunities per year, we identify the most attractive investments for our investors and ensure that our investors’ capital flows into the most promising opportunities.<\/p>\n<\/div><\/div>\n\n\n

\n
\n

Our Funds<\/h2>\n
\n
\n
\n
\n

<\/h3>\n

The current fund SHS VI had its final closing in July 2023.<\/p>\n

The targeted fund volume of EUR 200 million could significantly be overachieved with a final volume of ca. EUR 270 million and is thus more than doubling the predecessor fund\u2019s size.<\/p>\n

Our investor base comprises private and institutional investor groups with a long-term focus, including well-known family offices, pension funds, pension schemes, fund of funds, banks\/savings banks, churches, health insurance companies and industrial companies.<\/p>\n

They also include the European Investment Fund (EIF) and KfW. The SHS management is also invested with significant amounts in the fund, which ensures a high degree of identity of interests.<\/p>\n

The investment focus of the new fund SHS VI is on growing European healthcare companies, primarily in the DACH region, the Nordics, and the Benelux.<\/p>\n<\/div>\n

\n Investment Strategy<\/a>\n <\/div> <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n

LP Type (%)<\/h4>\n \n \n \n \n \n \n \n \n
Family Office<\/td>\n \n 39 %<\/span>\n <\/span>\n <\/span>\n <\/td>\n <\/tr>\n
Fund of Fund<\/td>\n \n 19 %<\/span>\n <\/span>\n <\/span>\n <\/td>\n <\/tr>\n
Pension<\/td>\n \n 16 %<\/span>\n <\/span>\n <\/span>\n <\/td>\n <\/tr>\n
Financial Institution<\/td>\n \n 10 %<\/span>\n <\/span>\n <\/span>\n <\/td>\n <\/tr>\n
Insurance<\/td>\n \n 6 %<\/span>\n <\/span>\n <\/span>\n <\/td>\n <\/tr>\n
HNI<\/td>\n \n 5 %<\/span>\n <\/span>\n <\/span>\n <\/td>\n <\/tr>\n
Other<\/td>\n \n 5 %<\/span>\n <\/span>\n <\/span>\n <\/td>\n <\/tr>\n <\/table>\n <\/div>\n
\n

LP Geographical base (%)<\/h4>\n \n \n \n \n \n \n \n \n
Germany<\/td>\n \n 54 %<\/span>\n <\/span>\n <\/span>\n <\/td>\n <\/tr>\n
Luxembourg<\/td>\n \n 19 %<\/span>\n <\/span>\n <\/span>\n <\/td>\n <\/tr>\n
Switzerland<\/td>\n \n 10 %<\/span>\n <\/span>\n <\/span>\n <\/td>\n <\/tr>\n
Denmark<\/td>\n \n 7 %<\/span>\n <\/span>\n <\/span>\n <\/td>\n <\/tr>\n
Spain<\/td>\n \n 4 %<\/span>\n <\/span>\n <\/span>\n <\/td>\n <\/tr>\n
Austria<\/td>\n \n 3 %<\/span>\n <\/span>\n <\/span>\n <\/td>\n <\/tr>\n
Other<\/td>\n \n 1 %<\/span>\n <\/span>\n <\/span>\n <\/td>\n <\/tr>\n <\/table>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n\n
\n
\n

Corporate Governance and Fund Structure<\/h2>\n<\/div>\n\n\n\n
\n
\n 01<\/span>\n The funds submit quarterly reports to investors in accordance with customary international standards and are audited annually.<\/span>\n <\/div>\n
\n 02<\/span>\n Ethical and sustainable criteria (ESG) have been incorporated into our internal ESG principles and within the fund contracts.<\/span>\n <\/div>\n
\n 03<\/span>\n The SHS funds are primarily asset-managing and tax transparent.<\/span>\n <\/div>\n <\/section>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n
\n
\n

Building European Healthcare Champions<\/h2>\n<\/div>\n<\/div>\n\n\n
\n
\n
\n \n
Development volume of SHS Funds<\/div>\n \n
\n \n \n \n \n \n \n
SHS I<\/td>\n \n <\/span>\n <\/span>\n <\/td>\n <\/tr>\n
SHS II<\/td>\n \n <\/span>\n <\/span>\n <\/td>\n <\/tr>\n
SHS III<\/td>\n \n <\/span>\n <\/span>\n <\/td>\n <\/tr>\n
SHS IV<\/td>\n \n <\/span>\n <\/span>\n <\/td>\n <\/tr>\n
SHS V<\/td>\n \n <\/span>\n <\/span>\n <\/td>\n <\/tr>\n
SHS VI<\/td>\n \n <\/span>\n <\/span>\n <\/td>\n <\/tr>\n <\/table>\n\n <\/table>\n \n<\/div><\/div>\n\n\n\n
\n
\n
Fund-Allocation<\/div>\n
\n
    \n
  • <\/span>Small cap<\/li>\n
  • <\/span>Growth<\/li>\n <\/ul>\n <\/div>\n \n \n \n \n
    Small cap <\/td>\n <\/tr>\n
    Growth <\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n \n \n<\/div><\/div>\n<\/div>\n\n\n\n
    \n
    \n

    The volume of SHS managed funds has grown consistently over time. Located in the heart of Europe the General Partner SHS has successfully invested into fast-growing healthcare and life science companies for more than 30 years.<\/p>\n\n\n\n

    Fund volume of SHS’ funds grew constantly over the various fund generations. From SHS III with a volume of ca. 50m EUR to a fund volume of ca. 270m EUR in the current fund SHS VI.<\/p>\n<\/div>\n\n\n\n

    \n

    SHS fund VI builds a portfolio of approximately 10-15 minority and majority stakes in companies of the targeted sector. The investments are spread over phases and investment occasions.<\/p>\n\n\n\n

    Target allocation of the SHS VI fund is a majority of investments into small-cap transactions, whereby additional return drivers for the fund will come from the growth company bucket. The regional focus of the fund is Europe.<\/p>\n<\/div>\n<\/div>\n\n\n\n

    \n
    \n

    Company History<\/h2>\n
    A Brief Summary About Our Funds.<\/div>\n\n
    \n \"\"\n
    \n

    1993<\/h3>\n

    The former McKinsey consultants Reinhilde Spatscheck, Dr. Bernhard Schirmers and Klaus Hentges found SHS.<\/p>\n <\/div>\n

    \n

    1994<\/h3>\n

    Closing of the 1st fund generation (SHS I) – Agreement of a joint venture with a Landesbank.<\/p>\n <\/div>\n \"\"\n

    \n

    2000<\/h3>\n

    Closing of the 2nd fund generation in the form of two funds (SHS IIa and IIb) with a focus on technology and growth respectively.<\/p>\n <\/div>\n

    \n

    2008<\/h3>\n

    Closing of the 3rd fund generation (SHS III), which invests in growth companies in the life sciences sector. The fund is currently in the disinvestment phase (i.L.)<\/p>\n <\/div>\n \"\"\n

    \n

    2015<\/h3>\n

    Closing of the 4th fund generation (SHS IV), which, like its predecessor fund, invests in companies from the life sciences\/medical technology sector in German-speaking countries.<\/p>\n <\/div>\n \"\"\n

    \n

    2019<\/h3>\n

    Closing of the 5th fund generation (SHS V). The fund invests mainly in the DACH region, but also in other selected European countries.<\/p>\n <\/div>\n \"\"\n

    \n

    2023<\/h3>\n

    Final Closing of the 6th fund generation (SHS VI). The fund invests in all European countries and has more than double the volume of its predecessor fund.<\/p>\n <\/div>\n <\/div>\n\n <\/div>\n\n

    \n
    \n
    <\/div>\n <\/div>\n
    \n
    \n \"\"\n <\/div>\n

    1993<\/h3>\n

    The former McKinsey consultants Reinhilde Spatscheck, Dr. Bernhard Schirmers and Klaus Hentges found SHS.<\/p>\n <\/div>\n

    \n
    <\/div>\n
    <\/div>\n <\/div>\n
    \n

    1994<\/h3>\n

    Closing of the 1st fund generation (SHS I) – Agreement of a joint venture with a Landesbank.<\/p>\n <\/div>\n

    \n
    <\/div>\n
    <\/div>\n <\/div>\n
    \n
    \n \"\"\n <\/div>\n

    2000<\/h3>\n

    Closing of the 2nd fund generation in the form of two funds (SHS IIa and IIb) with a focus on technology and growth respectively.<\/p>\n <\/div>\n

    \n
    <\/div>\n
    <\/div>\n <\/div>\n
    \n

    2008<\/h3>\n

    Closing of the 3rd fund generation (SHS III), which invests in growth companies in the life sciences sector. The fund is currently in the disinvestment phase (i.L.)<\/p>\n <\/div>\n

    \n
    <\/div>\n
    <\/div>\n <\/div>\n
    \n
    \n \"\"\n <\/div>\n

    2015<\/h3>\n

    Closing of the 4th fund generation (SHS IV), which, like its predecessor fund, invests in companies from the life sciences\/medical technology sector in German-speaking countries.<\/p>\n <\/div>\n

    \n
    <\/div>\n
    <\/div>\n <\/div>\n
    \n
    \n \"\"\n <\/div>\n

    2019<\/h3>\n

    Closing of the 5th fund generation (SHS V). The fund invests mainly in the DACH region, but also in other selected European countries.<\/p>\n <\/div>\n

    \n
    <\/div>\n
    <\/div>\n <\/div>\n
    \n
    \n \"\"\n <\/div>\n

    2023<\/h3>\n

    Final Closing of the 6th fund generation (SHS VI). The fund invests in all European countries and has more than double the volume of its predecessor fund.<\/p>\n <\/div>\n

    \n
    <\/div>\n <\/div>\n <\/div>\n\n
    \n
      \n